Titre :
  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Auteur : Clotet, Bonaventura ; Bellos, Nicholas ; Molina, Jean-Michel ; Cooper, David ; Goffard, Jean-Christophe ; Lazzarin, Adriano ; Wöhrmann, Andrej ; Katlama, Christine ; Wilkin, Timothy ; Haubrich, Richard ; Cohen, Calvin J.Calvin ; Farthing, Charles ; Jayaweera, Dushyantha ; Markowitz, Martin ; Ruane, Peter ; Spinosa-Guzman, Sabrina ; Lefebvre, Eric ; POWER 1 and 2 study groups
Informations sur la publication : Lancet, 369, 9568, (page 1169-1178)
Statut de publication : Publié, 2007-04
Sujet CREF : Médecine interne
Mots-clés MeSH : Adult
Drug Administration Schedule
Drug Therapy, Combination
Female
HIV Infections -- drug therapy
HIV Protease Inhibitors -- administration & dosage -- adverse effects -- therapeutic use
HIV-1
Humans
Male
Middle Aged
RNA, Viral -- blood -- drug effects
Ritonavir -- administration & dosage -- adverse effects -- therapeutic use
Sulfonamides -- administration & dosage -- adverse effects -- therapeutic use
Viral Load
Note : Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0140-6736 
info:doi/10.1016/S0140-6736(07)60497-8
info:pii/S0140-6736(07)60497-8
info:pmid/17416261
info:ulb-repo/set/1#23118